The myeloid transforming gene Evi-1 encodes a protein with two zinc ®nger domains, designated ZF1 and ZF2, with distinct DNA binding speci®cities. For the ®rst time we demonstrate that Evi-1 has transcriptional repressor activity which is directly proportional to the amount of Evi-1 protein in cells. Repression has been observed with two distinct promoters: the minimal HSV-1 tk promoter and a VP16 inducible adenovirus E1b minimal promoter. Optimal repression is DNA binding dependent and is mediated by either ZF1 or a heterologous GAL4 DNA binding domain (GAL4DBD) but is signi®cantly less ecient through the ZF2 binding site. Both GAL4DBD/ Evi-1 fusion and non-fusion proteins have been used to map the repressor activity to a proline-rich region located within amino acids 514 ± 724 between the ZF1 and ZF2 domains. Constitutive expression of mutant proteins lacking the repressor domain are defective for transformation of Rat1 ®broblasts demonstrating that this region is required for the oncogenic activity of the Evi-1 protein. These studies show that the Evi-1 gene encodes a transcriptional repressor and has important implications for the mechanism of action of the Evi-1 protein both in development and in the progression of some myeloid leukaemias.
Introduction
There is a strong correlation between the pathogenesis or progression of some myeloid malignancies and Evi-1 production. Normally Evi-1 is not produced in haemopoietic cells but expression is both temporally and spatially restricted during mouse embryogenesis suggesting a role in development (Perkins et al., 1991) . However, Evi-1 is frequently activated in both retrovirus-induced murine myeloid leukaemias and human acute myeloid leukaemias (AML) by translocations involving chromsome 3q26 (Morishita et al., 1992a) where the EVI-1 gene is located . Ectopic production of Evi-1 in murine myeloid cells results from insertion of retroviral LTR regulatory sequences within either non-coding exons one and two of the Evi-1 gene (Morishita et al., 1988) or within the distant ®m-3 locus (Bartholomew et al., 1989; Bartholomew and Ihle, 1991) . The mechanism of activation in AML is probably similar. For example, in one extensively characterised AML patient with inv (3) (q21q26) (Levy et al., 1994) , EVI-1 is probably activated by the juxtaposition of distant constitutive regulatory sequences of the Ribophorin I gene (Suzukawa et al., 1994) . Although the usual consequences of structural alterations is ectopic production of normal full length and alternatively spliced Evi-1 proteins (Bordereaux et al., 1990) , t(3;21)(q26;22) translocations in chronic myelocytic leukaemia create a novel fusion protein comprising the N-terminus of the AML1 gene, including the DNA binding runt homology domain, and the entire EVI-1 gene .
The more recent observation of EVI-1 production in some myelodysplastic syndrome, AML and acute promyelocytic leukaemia patients with no gross structural abnormalities of chromosome 3q26 suggests a more frequent role for EVI-1 in haemotologic disorders than originally anticipated (Russell et al., 1994; Dreyfus et al., 1995) . Furthermore, Evi-1 is oncogenic in Rat1 ®broblasts . Therefore, understanding the mechanism of action of Evi-1 will provide some important insights into leukaemogenesis.
Structurally, the 145 kd nuclear Evi-1 protein (Matsugi et al., 1990) is organised into at least three recognisable domains (Morishita et al., 1988) , two of which comprise seven and three repeats of the DNA binding Cys 2 -His 2 zinc ®nger motif. Both zinc ®nger domains, designated ZF1 and ZF2, have distinct DNA binding speci®cities. Bacterially derived GST-fusion proteins comprising either the ZF1 or ZF2 domains only, will bind the sequences GA(C/T)AAGA(T/ C)AAGATAA (ZF1 recognition sequence) (Delwel et al., 1993) and GAAGATGAG (ZF2 recognition sequence) (Funabiki et al., 1994) . Interestingly, the ZF1 recognition sequence is closely related to the GATA family recognition sequence and, furthermore, it has been shown to bind GATA-1 . The third domain, an acidic motif, is thought to be involved in transactivation (Morishita et al., 1988) .
The transcriptional regulatory properties of Evi-1 are unknown. Some evidence indicates that Evi-1 is a transactivator of gene expression. Both Evi-1 and an AML1/EVI-1 fusion protein variant, produced in chronic myelocytic leukaemia by the t(3;21)(q26;22) translocation, increase intra-cellular levels of AP1 and stimulate c-fos promoter activity , but it is not clear if this is a direct eect. Similarly, weak transactivation has been observed in reporter constructs containing the DNA recognition sequences for both the ®rst (ZF1) and second (ZF2) zinc ®nger domains (Morishita et al., 1995) . However, other evidence suggests that Evi-1 can repress gene expres-sion. For example Evi-1 or AML1/EVI-1 fusion proteins can dominantly suppress transactivation by the transcription factors GATA-1 or AML1 respectively Tanaka et al., 1995) . Although a DNA-binding competition mechanism has been proposed to explain these ®ndings, it is conceivable that Evi-1 might also act as a direct repressor. The recent identi®cation of a potential Evi-1 responsive gene, designated 150 B9-1, which is down regulated in Evi-1 expressing cells (Matsugi et al., 1995) is also consistent with repressor activity.
In this study we have examined the transcriptional regulatory properties of the full length Evi-1 protein.
We show for the ®rst time that Evi-1 functions as a repressor of gene transcription through either the ZF1 recognition site or a heterologous GAL4(1 ± 147) DNA binding domain (GAL4DBD). The Evi-1 repressor has been characterised using GAL4DBD fusion and nonfusion proteins which show that a repressor activity resides between the two zinc ®nger domains. In addition, we show that this region is essential to the oncogenic activity of the Evi-1 protein since mutant proteins no longer transform Rat1 ®broblasts. Clearly, these observations have signi®cant implications for the mechanism of action of the Evi-1 proto-oncogene in both development and leukaemia progression.
Results
Evi-1 has repressor activity which can be mediated by the heterologous DNA binding domain of GAL4
The Evi-1 ZF1 and ZF2 DNA recognition sequences were originally identi®ed by a PCR based selection protocol (Delwel et al., 1993; Funabiki et al., 1994) . Because of their arti®cial nature we initially used the heterologous GAL4DBD to investigate the transactivation properties of Evi-1. The Evi-1 gene was fused in frame downstream of GAL4DBD in the mammalian expression vector pSG424, creating a GAL4/Evi-1 fusion gene in the plasmid designated pGEvFL (Figure 1a ). Transient transfection of human kidney 293 cells with pGEvFL and the pGal4tkCAT reporter ( Figure 1a ) results in a signi®cant decrease in tk promoter activity as determined by CAT activity. The extent of repression of pGal4tkCAT correlates with the amount of pGEvFL transfected (Figure 2a , shaded bars) and the intracellular levels of the fusion protein ( Figure 2a) . Furthermore, Evi-1 is essential for repression since pSG424 (GAL4DBD) alone has no eect ( Figure 2b ). Optimal repression requires DNA binding but it is also observed in co-transfections with the pBLCAT2 reporter (Figure 1 ) which lacks the GAL4 recognition sequence (Figure 2a, open bars) . Similar results are also seen with the SV40 minimal early and adenovirus E1b promoters (not shown).
Although we see Evi-1 speci®c repression, the reporters used in this study can all be dramatically induced by the potent trans-activator Gal4-VP16 (not shown). Figure 1 The structure of the expression vectors pGEvFL and pSG424 with the GAL4 (1 ± 147) DNA binding domain (GAL4DBD), zinc ®nger domains 1 (ZF1) and 2 (ZF2) and the acidic domain (ac) indicated in grey, black and striped boxes. Also shown are the reporter constructs pGal4tkCAT and pBLCAT2 indicating the four copies of the GAL4 UAS (white box), the tk (grey box) and the CAT gene (black box) 0 0.156µg 0.3125µg 0.625µg 1.25µg 2.5µg 5µg 10µg
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igure 2 Evi-1 repressor activity in kidney 293 cells. (a) 2.5 mg of either pGal4tkCAT (black bars) or pBLCAT2 (white bars) and 1 mg pHSV b-gal were transiently transfected into cells with increasing concentrations of pGEvFL DNA as indicated. CAT activity is corrected for b-galactosidase activity and background as described in Materials and methods. Error bars indicate the maximum deviation of the mean from three independent transfections. Above is shown Western blot analysis of 293 cells transiently transfected with the indicated amounts of pGEvFL using the Evi-1-speci®c anti-sera 34597 (Clark and Bartholomew, unpublished) showing the 145 kd Evi-1 protein. (b) Cotransfections of increasing amounts of GAL4 (1 ± 147)DBD (pSG424) with the pGal4tkCAT reporter. Transfections were performed as described in (a)
Evi-1 represses VP16 mediated trans-activation
We next examined if Evi-1 could repress the induction of a minimal promoter by a trans-activator protein. We used the trans-activator protein VP16 fused to the DNA binding domain of lexA (lexAVP16) and the reporters pL8-CAT and pL8G5-CAT (Hollenberg et al., 1995) which have the E1b TATA box with eight copies of the lexA recognition sequence and ®ve copies of the GAL4 UAS (pL8G5-CAT only) all located upstream of the CAT gene (Figure 3a and b) .
Transient transfection studies in 293 cells show very low CAT activity which is dramatically induced in the presence of lexAVP16 (Figure 3a and b) . However, cotransfection with pGEvFL also, results in a substantial repression in CAT activity (Figure 3a) proportional to the amount of vector DNA used. No repression is observed with GAL4DBD alone (Figure 3a, pSG424) or with the L8.CAT reporter (Figure 3b) . Furthermore, Evi-1 does not repress production of lexAVP16 since pL8-CAT is induced equally in the presence or absence of pGEvFL (Figure 3b ). This demonstrates that Evi-1 expression inhibits lexAVP16 mediated transcriptional activation of the adenovirus E1b minimal promoter in a DNA binding dependent fashion.
Deletion mutagenesis of the Evi-1 repressor
A series of Evi-1 deletion mutants were created to localise the repressor activity. These were inserted into the pSG424 vector, generating GAL4/Evi-1 fusion proteins, and their repressor activity was assessed in transiently transfected 293 cells using the lexAVP16 induced pL8G5-CAT reporter assay (Figure 4a ). Each mutant produced the expected size protein with only minor variations in abundance (Figure 4b and c). Deletion of the N-terminus of the Evi-1 protein (pGEv514) had no signi®cant eect upon repressor activity, but further truncation to amino acid 725 (pGEv725) totally abolished transcriptional repression (Figure 4a, pGEv725) . Similarly, deletion of the Cterminus, including the second zinc ®nger domain ZF2, to amino acid 633 had no eect ( Figure 4a , pGEv11/ 633), but the repressor activity was substantially reduced upon further truncation to amino acid 573 ( Figure 4a , pGEv11/573). Expression of either ZF1 alone (pGEv11/ 289), ZF2 and the remaining C-terminus (pGEv725) or the acidic domain alone (pGEv877/928) each appear to have no or low (pGEv877/928) repressor activity. Therefore, the major repressor activity resides within amino acids 514 and 633 which are located between the ZF1 and ZF2 zinc ®nger domains.
Localisation of a minimal repressor domain
In order to identify a minimal region necessary for Evi-1 repressor activity, additional deletion mutants were 
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Figure 4 Repressor activity of GAL4/Evi-1 fusion protein deletion mutants. Transfections were performed as described in Figure 3 with the pL8.G5-CAT reporter either alone or with 1 mg pGEvFL or equimolar amounts of the expression vectors indicated. CAT activity is corrected for b-galactosidase activity in the same samples. (a) The ®gure shows the average of three independent transfections. Error bars as for Figure 2 . The structure of the deletion mutants are shown adjacent to the histogram, indicating the GAL4(1 ± 147) DNA binding domain (grey box), and Evi-1 zinc ®nger (black box) and acidic domains (striped box). Below, Western blot analysis of 293 cells transiently transfected with the indicated constructs using a GAL4DBD monoclonal antibody (RK5C1, Santa Cruz Biotech, Inc), b and c, 7.5% and 10% acrylamide gels respectively
Evi-1 Repressor C Bartholomew et al created and inserted into the pSG424 expression vector ( Figure 5a ) and their activity examined as before. Each construct produced similar levels of the expected size proteins ( Figure 5b ). When Evi-1 is deleted from the N-terminus to amino acid 514 and systematic Cterminal truncations are made which remove the acidic domain (pGEv514/876), the region between the acidic and ZF2 domains (pGEv514/803) and the ZF2 domain itself (pGEv514/724), there is no signi®cant reduction in the optimal repressor activity ( Figure 5a ). However, further deletion to amino acid 573 (pGEv514/573) substantially decreases repressor activity, although this 59 amino acid sequence still retains some activity (Figure 5a ). Deletion of 31 N-terminal amino acids from 514 to 545 (pGEv545/724) also substantially reduced repressor activity (Figure 5a ). Interestingly, deletion of this construct from the Cterminus to create pGEv545/633 generates a minimal construct with partially restored repressor function ( Figure 5a ) which is lost upon further deletion (pGEv545/573).
The Evi-1 protein functions as a transcriptional repressor through the ZF1 DNA binding site
The lexAVP16 inducible reporters pL8ZF1-CAT and pL8ZF2-CAT and the expression vector pRC/CMV FL (Figure 6a and b) were created to investigate if Evi-1 repressor activity is also mediated by the ZF1 and ZF2 recognition sequences. Transient transfection of 293 cells shows that the activity of both reporters are dramatically induced by lexAVP16
( Figure 6a and b) and that pRC/CMV FL directs the production of the expected 145 kd Evi-1 protein (not shown). However, lexAVP16 induced pL8ZF1-CAT activity is substantially reduced by pRC/CMV FL ( Figure 6a ). Repression is DNA binding dependent since co-transfection of 100 ng of pRC/ CMV FL with the reporter pL8-CAT, which lacks an Evi-1 recognition sequence, has no eect upon lexAVP16 induced reporter activity (Figure 6c ). Furthermore, transfection of 1 mg pRC/CMV vector has no eect upon lexAVP16 induced reporter activity (Figure 6a ). In contrast to ZF1 dependent transcriptional repression, ZF2 mediated repression requires transfection of considerably more pRC/ CMV FL expression vector (Figure 6b ). Signi®cant, Evi-1 Repressor C Bartholomew et al although inferior, repression is also observed at these DNA concentrations (1 ± 2.5 mg) even without a ZF2 binding site (Figure 6c ).
Co-localisation of the ZF1 and GAL4DBD Evi-1 repressor sequences
To demonstrate that the mechanism of Evi-1 repression is the same for both the native protein and GAL4DBD fusion proteins, the location of the sequences essential for repressor activity were re-examined using the pL8ZF1-CAT reporter. Repressor activity of the GAL4DBD fusion protein is lost upon C-terminus deletion of amino acid residues 633 to 573 ( Figure 5 ). Therefore, three directly comparable deletion constructs pRC/CMV Ev11/633, pRC/CMV Ev11/573 and pRC/CMV Ev11/513 were created ( Figure 7 ) and their activity examined in transiently transfected 293 cells. pRC/CMV Ev11/633 has similar repressor activity to the full length Evi-1 protein but this is lost upon deletion of 60 amino acids (Figure 7 pRC/CMV Ev11/573), demonstrating that the ZF1 mediated repressor activity observed with the native Evi-1 protein is the same as described for the GAL4DBD/ Evi-1 fusion proteins.
The repressor domain is required for Evi-1 mediated transformation of Rat1 ®broblasts The Rat1 transformation assay was used to examine the importance of the repressor domain to the activity of the Evi-1 protein. Recombinant retroviral vectors containing either an evi-1 full length cDNA (p50-M-5.6-neo) or a deletion mutant (p50-M-520/725-neo) cDNA lacking the repressor domain, were constructed from the vector p50-M-X-neo (Figure 8a ) and virus generated and used to infect Rat1 cells as described in Materials and methods. Both viruses, containing either full length or mutant Evi-1, produced similar titres of approximately 10 4 /ml and directed the production of the expected size proteins in G418 selected populations of infected Rat1 cells (Figure 8b ). These cells were examined for anchorage independent growth in soft agar as described previously . Cells infected with full length Evi-1 (p50-M-5.6-neo) formed macroscopic colonies in soft agar within 14 to 21 days after seeding while either vector alone (p50-M-X-neo) or mutant (p50-520/725) infected cells produced fewer, predominantly tiny colonies (Table 1) . The p50-M-5.6-neo infected colonies were picked and readily established in culture and shown to be expressing the Evi-1 protein (Figure 8c ). These results con®rm that the repressor domain de®ned by deletion mutagenesis is essential to the biological activity of the Evi-1 protein. Bartholomew, unpublished) . Repression is eciently mediated by the speci®c interaction of either the Evi-1 ZF1 or heterologous GAL4DBD domains with DNA and to a lesser extent by the ZF2 domain. The reasons for poor ZF2 repression are unclear since both in vitro translated or crude cell extract derived Evi-1 proteins bind the ZF2 site in vitro (data not shown). Possibly the protein does not interact eciently with this arti®cially de®ned sequence in vivo or alternatively the conformation of the Evi-1/ZF2 complex could mask the repressor activity. Optimal Evi-1 mediated repressor activity requires binding to DNA, but DNA binding independent repression is observed at higher intracellular protein concentrations. Possibly, the reporter constructs used contain either cryptic or novel recognition sequences for Evi-1. Alternatively, the direct interaction of Evi-1 with DNA may not be required for repression of some promoters, repression being mediated by direct contact with certain trans-activators in a manner analogous to the regulation of the homeobox protein hunchback by KruÈ ppel (Zuo et al., 1991) .
Other studies suggest that Evi-1 may also act as a trans-activator. Moderate trans-activation (2 ± 3-fold) is observed in HEC-1B and NIH3T3 cells using arti®cial constructs with both ZF1 and ZF2 recognition sequences located upstream of the minimal tk gene promoter (Morishita et al., 1995) . This might suggest Evi-1 is a bi-functional protein which acts as both a repressor or a transactivator, like KruÈ ppel for example (Zuo et al., 1991) , in a manner which is dependent upon the architecture of the target gene promoter. To clarify this issue, it will be necessary to identify and characterise the regulation of authentic Evi-1 target genes. Interestingly, one potential target gene, 150 B9-1, has been described which appears to be repressed by Evi-1 (Matsugi et al., 1995) .
Deletion of mutagenesis shows that the repressor activity of the Evi-1 protein localises between the amino acids 514 to 724 (Figure 9 ). Inactive fusion proteins which lack this region retain their nuclear localisation, demonstrating that the loss of function is not due to changes in subcellular localisation (C Bartholomew, unpublished) . The precise structural requirements for a repressor domain are unknown but many proteins share primary amino acid regions rich in alanines, prolines or glutamines (Cowell, 1994) . Interestingly, Evi-1 has two clusters of proline residues from amino acids 258 ± 381 and 502 ± 713, the latter correlating with the major Evi-1 repressor activity (Figure 9 ). The 210 amino acid sequence which retains optimal repressor activity is depicted in Figure 9 . N-terminal truncation of an additional 31 residues results in a signi®cant drop in repressor activity which coincides with the deletion of ®ve proline residues in a 19 amino acid stretch (Figure 9 ). In addition, deletion analysis shows that proline rich region 573 to 633 is also important (Figure 9) . Therefore, the majority of the repressor activity appears to reside between amino acids 514 to 633.
The Evi-1 repressor domain is necessary for oncogenic activity in Rat1 ®broblasts demonstrating that it is required for the biological activity of the protein. It will be interesting to see if this function is also required for other properties attributed to Evi-1 including the transformation of haemopoietic cells in leukaemia, blocking both G-CSF and EPO responsiveness in 32D (Morishita et al., 1992b) and erythroid progenitors respectively and also normally during development (Perkins et al., 1991) . Previous studies have shown that the ZF2 domain is also required for transformation and increased AP1 activity in Rat1 cells . However, it is not clear if the AP1 activity is essential to Evi-1 mediated transformation or if this activity is also elevated in Evi-1 expressing leukaemias. Curiously, only poor transcriptional repression is mediated by the ZF2 site and therefore it will be interesting to determine if the repressor region is required for increased AP1 activity.
The observation that Evi-1, GATA and AML-1/ EVI-1, AML1 bind to similar sequences and our demonstration that Evi-1 has repressor activity, might be very relevent to oncogenic activity since these proteins are essential to haematopoietic cell development (Shivdasani and Orkin, 1996) . They would have antagonistic eects on a subset of shared target genes: GATA and AML1 increasing and Evi-1 or AML-1/ EVI-1 suppressing expression respectively. In the case of AML-1/EVI-1, the protein may repress several target genes including those recognised by the ZF1 and ZF2 domains of Evi-1 and an entirely new set of genes recognised by AML-1 . Linking the DNA binding domain of AML-1 to a repressor may be essential to its oncogenic activation since another common fusion partner, ETO, is also a repressor (Meyers et al., 1995) .
Deregulated expression and structural alterations of transcription factors is a common theme in tumourigenesis (Rabbitts, 1994) . It is beginning to emerge that in addition to the activation of gene transcription, repression is also important to the transforming activity of nuclear oncogenes including Figure 9 Schematic representation of the Evi-1 repressor domain. The Evi-1 protein is shown with the ZF1, ZF2 (black box), repressor (grey box) and acidic (striped box) domains highlighted. Below is shown the amino acid sequence from residues 514 to 724 which have optimal repressor activity. Boxed is the minimal region which retains substantial repressor activity. Underlined are regions which are also important for optimal repressor activity. Individual proline residues are also underlined Evi-1 Repressor C Bartholomew et al v-jun (Havarstein et al., 1992 ), v-rel (Smardova et al., 1995 and c-myc (Li et al., 1994) . Furthermore, other oncogenes are implicated in leukaemia progression have been shown to function as repressors of transcription including, v-erbA (Baniahmad et al., 1992) , AML1/ETO (Meyers et al., 1995) and bmi-1 (Bunker and Kingston, 1994) . Evi-1 also has a transcriptional repressor activity that is required for transformation in addition to the previously described trans-activation function (Morishita et al., 1995) . Several interesting possibilities exist for the potential physiological targets of transcriptional repressors which would contribute to tumourigenesis, including repression of: (1) a limited group of tissue speci®c genes, as for the erythroid and myeloid speci®c genes regulated by v-erbA (Zenke et al., 1988) and AML1B (Zhang et al., 1994) respectively; (2) key transcriptional control factors, eg GATA, SCL MYB, AML1 and PU.1, regulating haematopoietic development (Shivdasani and Orkin, 1996) ; (3) negative regulators of cell proliferation such as the cyclin-dependent kinase inhibitors p15INK4A, p16INK4B, p21 and p27 (Hirama and Koeer, 1995) and (4) negative regulators of apoptosis such as the Bcl-2 antagonists Bax (Oltvai et al., 1993) and Bcl-X (Boise et al., 1993) . Clearly, selective suppression of gene expression might play a key role in Evi-1 mediated leukaemogenesis. Identifying the critical target genes is an important step to understanding this process.
Materials and methods

Cells and cell culture
Adherent human 293 adenovirus transformed foetal kidney cells (ECACC CRL 1573), derivative BOSC 23 cells (Pear et al., 1993) and NIH3T3 cells were grown in a modi®cation of Eagle's minimal essential medium with double concentrations of amino acids and vitamins (SLM, Gibco-BRL), 10% foetal calf serum (Advanced Protein Products Ltd). In transient transfection experiments, cells were supplemented with 100 mg/ml and 37.5 mg/ml of streptomycin and penicillin respectively. Rat1 cells were maintained in Dulbecco modi®ed Eagle medium (DMEM) with 5% newborn calf serum.
Plasmid construction
Reporter constructs The CAT reporter constructs pBLCAT2 (Luckow and SchuÈ tz, 1987) , pGal4tkCAT (Shi et al., 1991) , pL8G5-CAT and pL8-CAT (Hollenberg et al., 1995) have been described previously. To create the pL8ZF1-CAT and pL8ZF2-CAT reporter, phosphorylated ZF1 or ZF2 recognition sequence complementary oligonucleotides with a GATC overhang were annealed and ligated and fragments corresponding to four copies were puri®ed by PAGE and ligated into the BamHI site of pBluescript KS II (Stratagene) to create pSKZF1 4 and pKSZF2 4 . The four copies of either ZF1 or ZF2 were excised as PstI/XbaI fragments and inserted into PstI/HindIII digested pL8G5-CAT replacing the ®ve copies of the GAL4 UAS to create either pL8ZF1-CAT or pL8ZF2-CAT. Reporters lacking the tk promoter were made by excising a BamHI/BglII promoter fragment from pBLCAT2 and pGal4tkCAT and re-ligating to create pBLCAT2-vetk and pGal4-vetkCAT, respectively.
Expression vectors
The expression vector lexAVP16 has been described previously (Hollenberg et al., 1995) . To create pRC/CMV FL, Evi-1 was PCR ampli®ed from pBS21 (Morishita et al., 1988) using the oligonucleotide primers FLE5 and FLE6, digested with BamHI/XbaI and inserted into pBluescript KS II to produce pKSII5.6. A BamHI (end-®lled)/NotI Evi-1 fragment from pKSII5.6 was ligated into the HindIII (end-®lled)/NotI site of pRC/CMV (pRC/CMV) creating pRC/CMV FL. pRC/CMV Ev322, pRC/CMV Ev11/633, pRC/CMV Ev11/573 and pRC/CMV Ev11/573 were all created by inserting a NotI digested PCR fragment derived by ampli®cation of pBS21 with FLE8 and either ED12, ED7, ED6 or ED5 oligonucleotides respectively into the NotI site of pRC/CMV. The GAL4/Evi-1 fusion protein pGEv877/928 was created by inserting an EcoRI/SstI digested PCR product derived from TAD1E/ TAD2 into the EcoRI/SstI site of pSG424 (Sadowski and Ptashne, 1989) . The vectors pGEv877 (TAD1E/TAD3), pGEv804 (TAD4E/TAD3) and pGEv725 (TAD5E/TAD3) were created similarly using oligonucleotide primers indicated. The full length GAL4/Evi-1 fusion protein was generated by inserting EcoRI/NdeI digested PCR products, generated by ampli®cation of pBS21 DNA with oligonucleotides TAD6E and FLE6, into EcoRI/NdeI digested pGEv725 DNA to generate pGEvFL. pGEv222 and pGEv514 were created similarly using TAD7E/FLE6 and TAD8E/FLE6 oligonucleotide primers respectively. The 3' deletion constructs pGEv11/289 (TAD6E/ED1), pGEv11/ 422 (TAD6E/ED2), pGEv11/513 (TAD6E/ED3), pGEv11/ 573 (TAD6E/ED4), pGEv11/633 (TAD6E/ED5) and pGEv223/633 (TAD7E/ED5) were also created by PCR using the indicated oligonucleotide primers and inserting EcoRI/NotI digested fragments into pSG424 which had been modi®ed by inserting NotI linkers in the SstI to create pSG424NotI. The minimal constructs pGEv521/876 (TAD8E/ED10), pGEv521/803 (TAD8E/ED9), pGEv521/ 724 (TAD8E/ED8), pGEv521/573 (TAD8E/ED8), pGEv545/724 (TAD15E/ED8), pGEv545/674 (TAD15E/ ED11), pGEv545/633 (TAD15E/ED7) and pGEv545/573 (TAD15E/ED6) were created in the same way using the oligonucleotides indicated. In all cases the gene fusion junction was veri®ed by sequencing using the oligonucleotide primer GAL4seq (GAGTAGTAACAAAGGT-CAAAG). Deletion mutants are numbered according to the published Evi-1 amino acid sequence (Morishita et al., 1988) .
Retroviral vectors NotI linkers were inserted into the EcoRI site of pKSII5.6 and the Evi-1 cDNA excised as a NotI fragment and inserted into the NotI site of the retroviral vector p50-M-X-neo to create p50-M-5.6-neo. p50-M-D520/725-neo was created in two steps. Firstly, a NotI/BamHI digested PCR ampli®ed pBS21 fragment using oligonucleotides NotI and 520 was inserted into the NotI/BamHI site of p50-M-X-neo. Secondly, a similarly ampli®ed fragment using oligonucleotides 725 and EcoRI, digested with BamHI/EcoRI was inserted into the BamHI/ EcoRI site of the ®rst construct creating p50-M-D520/725.
Preparation of PCR fragments
Speci®c DNA sequences were ampli®ed by PCR with Taq DNA polymerase (Promega). To amplify sequences, 10 ng plasmid DNA was mixed with 280 ng, speci®c oligonucleotide primers in 100 ml solution of 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl 2 , 0.1% Triton X-100, 200 mM deoxynucleotide triphosphates (Pharmacia) and 2.5 U Taq DNA polymerase. Ampli®cation was achieved in a Perkin-Elmer Cetus thermal cycler by 30 cycles of 30 s at 948C, 30 s at 50 ± 558C and 1 ± 2 min at 728C, followed by a ®nal 10 min at 728C extension time. The PCR products were resolved by agarose gel electrophoresis and puri®ed by Geneclean (BIO 101 Inc).
Oligonucleotide PCR primers
5'
primers FLE5,  GAATTGGATCCCACGAACC-CATGGCGCCTGACATC; FLE8, GAATTGCGGCCGC-CACGAACCCATGGCGCCTGACATC; TAD1E, AGCT-TGAATTCGATTTATTGGATGATG; TAD4E, AGCTT-GAATTCGAGAACGGCAACATGTC; TAD5E, AATT-GAATTCACCTGCAGGTACTGTGGC; TAD6E, AATT-GAATTCGCGCCTGACATCCACG; TAD7E, AATTG-AATTCGGACAAATGTTCAGCAC; TAD8E, AAGC-GAATTCGCATTCTCTCAATCAATG; TAD15E, AAG-CGAATTCCTGCAGAAGGGAAGCTC; NotI, AATTG-CGGCCGCTGCTGTTCATGAAGAGTGAAGAGG; 725,  AAGCTGGATCCACCTGCAGGTACTGTGG. 3' primers FLE6, AGCTATCTAGATCATACATGGCT-TATGGACTGGAT; TAD2, ATCCGAGCTCATCTCC-AGGGCA; TAD3, ATCCGAGCTCTCATACATGGC TTATG; ED1, GAATGCGGCCGCTAAGCAGGATG CCTATTGGTGC; ED2, AATTGCGGCCGCTCACTCTT TATCACTTTCAAG; ED3, AATTGCGGCCGCTCA-CTGGAAAAAACGGGAGG; ED4, AATTGCGGCCG-CTCAAGGCTTCGAGGGGCCTG; ED5, AATTGCGG-CCGCTCAAGTGGGTCTGGCATGCTG; ED6, AATT-GCGGCCGCTCAAGGCTTCGAGGGGCCTG; ED7, A-ATTGCGGCCGCTCAAGTGGGTCTGGCATGCTG; ED8, AATTGCGGCCGCTCAGTAGCGCTCTTTCCC-CT; ED9, AATTGCGGCCGCTCAATGTTTCTTCAG-GTGTC; ED10, AATTGCGGCCGCTCATGAATTTT-GGCTGGTTG; ED11, AATTGCGGCCGCTCATGCT-GACATTTGCGGGTG; ED12, AATTGCGGCCGCTCA-AGGACTAGCGGGTATC; T7, TAATACGACTCACTA-TAGGG; 520, AAGCTGGATCCGTACATTGATTGA-GAGA; EcoRI, AGCTGAATTCATACATGGCTTATG-GACTGGAT.
Viral infection and assay for growth in soft agar
Replication de®cient retroviral stocks were prepared by transient transfection of BOSC-23 cells essentially as described by Pear et al. (1993) . Conditioned medium was harvested 48 ± 72 h after transfection and either stored in 7708C, titred on NIH3T3 cells or used to infect Rat1 cells. Viral infections were performed by exposing cells to virus with 8 mg of polybrene per ml at 378C and resistant populations were selected in the presence of 800 mg/ml of active G418 for 8 ± 10 days 48 h post infection.
Trypsinised cells were suspended in DMEM containing 0.3% agar and 20% foetal calf serum. A layer of this suspension was plated onto a bottom layer containing 0.6% agar. Cells were plated at a density of 1610 3 cells per 6 cm dish and colonies were counted after 21 days. Three independent assays were performed.
Western blot analysis
Whole cell extracts were prepared as described by Marais et al. (1993) . Brie¯y transiently transfected cells in 60 mm dishes were washed in cold PBS and lysed in 75 ml of lysis buer (20 mm HEPES, 5 mM EDTA, 10 mM EGTA, 5 mM NaF, 0.1 mg/ml okadaic acid, 10% glycerol, 1 mM DTT containing 0.4 M KCl, 0.4% Triton X-100 and protease inhibitors; 5 mg/ml leupeptin, 5 mg/ml aprotinin, 5 mg/ml pepstatin A, 1 mM benzamidine, 50 mg/ml PMSF. Cell lysates were scraped from plates and clari®ed by centrifugation in a microfuge, 48C, quantitated using coomassie protein assay reagent (Pierce) and stored at 7708C. Proteins were examined by SDS±PAGE, transferred to Hybond TM -ECL nitrocellulose, incubated with appropriate antibodies and proteins visualised using the Amersham ECL Western blotting detection system.
Transfections, CAT, luciferase and b-galactosidase assays
Calcium phosphate precipitates of supercoiled plasmid DNA expression vectors and reporter constructs were added dropwise to cell culture medium and incubated for 4 h after which the medium was replaced and cells were incubated for a further 36 ± 48 h. DNA concentrations were kept constant by adding appropriate amounts of pBluescript KS II to calcium phosphate precipitates. The chloramphenicol acetyltransferase (CAT) and b-galactosidase activities (pHSV b-Gal) were measured as described previously (O'Prey et al., 1993) . Both CAT (quanti®ed when less than 30% conversion of substrate had ocurred) and luciferase activities were measured, normalised for transfection eciency by using the b-galactosidase activity as a control and expressed as a percentage of the reporter construct alone, which was taken as 100%. To allow an accurate measure of tk promoter activity, the samples are also corrected for CAT activity derived from cryptic promoters (5 ± 10% of total CAT activity) located in the plasmid pBLCAT2 (Boshart et al., 1992) utilising the promoterless constructs pGal4-vetkCAT and pBLCAT2-vetk. Each transfection was repeated at least twice.
